Table 2.
Change from baseline in NMSS domain scores in the LCIG treatment group
| NMSS domain | Visit, mean (SD) | |||
|---|---|---|---|---|
| Month 3 (n = 44) |
Month 6 (n = 40) |
Month 12 (n = 38) |
Final (n = 40) |
|
| Cardiovascular including falls | −1.7 (4.3)a | −0.8 (3.0) | −0.8 (3.3) | −0.7 (3.2) |
| Sleep/fatigue | −6.8 (8.7)d | −5.9 (8.0)d | −5.6 (8.9)c | −5.4 (8.7)c |
| Mood/cognition | −7.8 (14.3)c | −7.6 (13.5)b | −8.8 (13.9)c | −8.4 (13.7)c |
| Perceptual problems/hallucinations | −1.1 (4.1) | −1.5 (4.2)a | −2.0 (5.0)a | −1.9 (4.9)a |
| Attention/memory | −2.1 (8.0) | −1.3 (8.3) | −1.8 (7.8) | −1.9 (7.7) |
| Gastrointestinal tract | −5.7 (6.4)d | −4.4 (6.7)c | −3.8 (6.4)c | −3.8 (6.3)c |
| Urinary | −7.4 (10.7)d | −5.9 (10.5)b | −5.9 (9.9)c | −5.5 (9.9)b |
| Sexual function | −1.3 (6.4) | −0.5 (5.7) | −0.3 (7.2) | −0.2 (7.0) |
| Miscellaneous | −5.7 (9.5)c | −5.9 (8.4)d | −4.9 (9.5)b | −4.7 (9.3)b |
“Final” represents the last observation carried forward
LCIG levodopa–carbidopa intestinal gel, NMSS Non-Motor Symptom Scale, SD standard deviation
a p < 0.05
b p < 0.01
c p < 0.001
d p < 0.0001